Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis a vaccine + diphtheria and tetanus toxoids and acellular pertussis vaccine + haemophilus b conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a pentavalent combination vaccine designed to provide active immunization against five major pathogens: Hepatitis A virus (HAV), *Corynebacterium diphtheriae*, *Clostridium tetani*, *Bordetella pertussis*, and *Haemophilus influenzae* type b (Hib). The vaccine combines inactivated viral particles, bacterial toxoids, and conjugated polysaccharides into a single formulation to simplify pediatric or adult vaccination schedules. While combination vaccines containing DTaP, Hib, and Hepatitis B (e.g., Vaxelis) are standard in many regions, this specific formulation substituting Hepatitis A for Hepatitis B was primarily developed and evaluated in clinical research settings by Sanofi (formerly Aventis Pasteur) to address specific epidemiological needs where Hepatitis A immunization is prioritized alongside the primary pediatric series.
- Other names
- DTaP-HepA-Hib vaccineDTaP-Hib-HepA vaccinepentavalent DTaP-HepA-Hib vaccine
02
Targets
PRN (Pertactin)Diphtheria toxinFHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)Hepatitis A virus capsid proteinPRNP (Cellular Prion Protein)
Beyond the preview
Go deeper on hepatitis a vaccine + diphtheria and tetanus toxoids and acellular pertussis vaccine + haemophilus b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis a vaccine + diphtheria and tetanus toxoids and acellular pertussis vaccine + haemophilus b conjugate vaccine.